Stay updated with breaking news from Membrane Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Morgan Stanley restated their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $42.00 target price on the stock. A number of other equities analysts have also commented on the stock. HC Wainwright reissued a buy rating and […]
Bicycle Therapeutics (NASDAQ:BCYC – Free Report) had its price target reduced by JMP Securities from $46.00 to $44.00 in a research report released on Friday, Marketbeat Ratings reports. They currently have an outperform rating on the stock. Separately, EF Hutton Acquisition Co. I reiterated a buy rating and set a $55.00 price target on shares […]
HC Wainwright reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $57.00 price objective on the stock. BCYC has been the topic of a number of other reports. EF Hutton Acquisition Co. I reiterated a buy rating and […]
Bicycle Therapeutics (NASDAQ:BCYC – Free Report) had its target price cut by Needham & Company LLC from $48.00 to $46.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other equities research analysts have also issued reports on the stock. […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) CEO Kevin Lee sold 1,498 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $25.10, for a total value of $37,599.80. Following the completion of the transaction, the chief executive officer now owns 323,601 […]